FOR RELEASE IN SWITZERLAND – THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.

Hoofddorp, the Netherlands, 3 December 2019. IGEA Pharma N.V. (SIX: IGPH) today announced the convening of an extraordinary general meeting (the “EGM”) for Wednesday, 8 January 2020. The EGM will resolve on the acquisition of the spin-off of Meditalia S.r.l. and on the proposal to authorize the management board to issue new shares (with respect to the acquisition of Meditalia, see also IGEA’s press release of 20 November 2019). IGEA plans to raise approximatively EUR 5 million gross proceeds through a capital increase in order to finance the further commercialization of its product portfolio which will include also the med-tech products of the planned spin-off of Meditalia S.r.l. IGEA expects to carry out its fundraising between March and April 2020. As previously announced, up to EUR 1 million new funds are committed by certain of the current shareholders of Meditalia S.r.l.

Furthermore, the agenda items of the EGM will include a proposal for an amendment of the articles of association in order to introduce a one-tier board structure as well as the appointment of non-executive directors.

The convening notice including agenda, explanatory notes and proxy material will be disclosed and publicly available on Friday, 6 December 2019 after market close.

About IGEA

IGEA is a group focused on health-tech products and devices operating on the US market. IGEA commercialize Alz1, an at-home lab testing kit to measure non ceruloplasmin bound copper (generally defined as “free” copper) in the bloodstream and Alz1 Tab, a natural dietary supplement designed to reduce and control heavy metal contents in the bloodstream. “Free” copper is a risk factor associated with Alzheimer’s and diabetes type II. Monitoring and normalizing “free” copper can contribute to reduce the risk of Alzheimer’s and diabetes type II respectively.

IGEA is listed on the SIX Swiss Exchange under the ticker IGPH and is headquartered in Hoofddorp, the Netherlands.

For further information, please visit the IGEA website at https://www.igeapharma.nl/

IGEA Pharma N.V. Investor Relations: https://www.igeapharma.nl/investors-relations/

Contact

Vincenzo Moccia, CEO
Tel +31 23 568 94 94/ +39 340 583 09 33
moccia@igearesearch.com

Patrick Pozzorini, CFO
Tel +31 23 568 94 94/ +41 79 314 41 43
pozzorini@igearesearch.com

IGEA Pharma N.V.
Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands
ir@igearesearch.com

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.

Disclaimer

This document does neither constitute an offer to buy or to subscribe for securities of IGEA Pharma N.V. nor a prospectus within the meaning of applicable Swiss laws and regulations or the SIX Swiss Exchange Listing Rules. Investors should make their decision to buy or exercise subscription rights or to buy or to subscribe to shares of IGEA Pharma N.V. solely based on the official prospectus (the “Prospectus”) to be published by IGEA Pharma N.V. in due course. Investors are furthermore advised to consult their bank or financial adviser before making any investment decision.

This publication may contain specific forward-looking statements, e.g. statements including terms like “believe”, assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed
in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA Pharma N.V. assumes no responsibility to update forwardlooking statements or to adapt them to future events or developments.

The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.
This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any state of the United States and the District of Columbia), Canada, Japan, Australia or any jurisdiction into which the same would be unlawful. This announcement does not constitute or form a part of any offer or solicitation to purchase, subscribe for or otherwise acquire securities in the United States, Canada, Japan, Australia or any jurisdiction in which such an offer or solicitation is unlawful. IGEA Pharma N.V.’s shares have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”) or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, within the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. Subject to certain exceptions, the IGEA Pharma N.V. shares are being offered and sold only outside the United States in accordance with Regulation S under the Securities Act. There will be no public offer of these securities in the United
States.

The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the
United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.

This document does not constitute an offer of securities to the public of the securities referred to herein in any member state of the European Economic Area (the “EEA”). Any offer of securities referred to in this document to persons in the EEA will be made pursuant to an exemption under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) as implemented in member states of the EEA, from the requirement to produce a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. Any offer of securities to the public that may be deemed to be made pursuant to this communication in any EEA member state that has implemented the Prospectus Regulation is only addressed to qualified investors in that member state within the meaning of the Prospectus Regulation and such other persons as this document may be addressed on legal grounds. For the purposes of this paragraph, the
expression an “offer to the public” in relation to any securities in any member state means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities.

Documents for download:
Press release in PDF